VHL and neoplasm: Tumor mutation burden (TMB) and VHL mutation play a crucial role in the management of patients with clear cell renal cell carcinoma (ccRCC), but the time‐consuming and expensive high‐throughput sequencing methods severely limit their clinical applicability.